Assess the QMS Framework
Evaluate whether quality governance, procedures, responsibilities, workflows and records are complete, connected and appropriate for the organization’s regulated activities.
Independent, risk-based assessment of GxP quality-system design, implementation and effectiveness for pharmaceutical, biotechnology, clinical research, laboratory, manufacturing and pharmacovigilance organizations seeking stronger compliance, inspection readiness and sustainable quality oversight.
A meaningful gap assessment does not only verify whether required SOPs exist. It evaluates whether quality processes are understood, consistently executed, supported by reliable evidence and capable of identifying and controlling systemic risk.
Evaluate whether quality governance, procedures, responsibilities, workflows and records are complete, connected and appropriate for the organization’s regulated activities.
Review selected quality records, decisions, metrics, investigations and management evidence to determine whether written controls are consistently implemented.
Classify findings by regulatory and operational significance and translate them into a phased, practical improvement roadmap.
Quality systems may appear complete because procedures exist, while operational evidence reveals inconsistent decisions, weak escalation, repeat findings and limited management visibility.
SOPs describe an ideal process, but teams use informal workflows, local workarounds or undocumented decision paths.
Deviations, CAPAs, changes, audits, complaints and vendor issues are managed separately without identifying shared risks or systemic patterns.
Roles, quality decision rights, escalation thresholds and management responsibilities are unclear or inconsistently applied.
Dashboards measure completed tasks and closure rates but do not show recurrence, residual risk, control effectiveness or emerging quality trends.
The engagement can assess the complete QMS, selected quality processes, one regulated function, one site or a specific area of inspection concern.
Broad evaluation of quality governance, core QMS processes, documentation, oversight, metrics and operational implementation.
Focused assessment of quality controls within clinical operations, pharmacovigilance, laboratories, manufacturing, IT or another regulated function.
Independent readiness assessment designed to identify high-risk quality-system weaknesses before regulatory inspection.
Evaluation of whether the existing quality system can support increased products, studies, vendors, sites, technologies or organizational complexity.
Independent review of whether completed remediation actions have produced sustainable and measurable improvement.
Independent assessment of QMS maturity and compliance exposure during acquisition, investment, licensing, partnership or vendor-selection decisions.
The final assessment scope is adapted to the organization’s GxP activities, product lifecycle, clinical programs, systems, outsourcing model and regulatory exposure.
The process combines document review, interviews, record sampling, workflow evaluation and management discussion to assess both system design and operational effectiveness.
Understand the organization, products, studies, sites, vendors, systems, regulatory responsibilities and assessment objectives.
Review quality manuals, procedures, organization charts, metrics, audit histories, management reviews and known quality concerns.
Evaluate process understanding, responsibilities, escalation, decision-making and differences between documented and actual practice.
Review selected deviations, CAPAs, changes, audits, training records, vendor files and management evidence.
Assess process design, operational effectiveness, systemic weaknesses, regulatory exposure and quality-system maturity.
Deliver evidence-based findings, risk classifications, quick wins and a phased improvement roadmap.
Deliverables are tailored to the assessment objective, intended audience, regulatory context and level of remediation support required.
Assessments can be delivered proactively during growth or urgently when inspection findings, repeat deviations or major organizational changes indicate potential systemic weakness.
Leadership needs an independent view of quality-system risk before regulatory inspection.
Similar observations continue across audits, functions, vendors or sites.
Existing controls no longer support increased products, studies, vendors, systems or locations.
The organization is entering clinical development, manufacturing, pharmacovigilance or another regulated activity.
Quality systems require independent evaluation before integration or harmonization.
Leadership needs a clear baseline before designing a broad corrective action program.
Greater reliance on CROs, laboratories, manufacturers or technology vendors requires stronger quality oversight.
Procedures exist, but repeat deviations, CAPAs and quality signals suggest that controls are not working effectively.
An independent quality-system gap assessment gives leadership a realistic view of current control, unresolved risk and the actions required to strengthen compliance and operational reliability.
Identify systemic weaknesses before they become major findings, regulatory commitments or operational failures.
Direct resources toward the highest-impact gaps instead of attempting to revise every process at the same time.
Provide management with a clear view of maturity, residual risk, dependencies and required quality investments.
Common questions from quality leaders, executives and regulated life sciences organizations considering an independent QMS assessment.
Yes. The assessment can cover quality governance, document control, training, deviations, CAPA, change control, risk management, audits, vendor oversight, metrics and management review.
Yes. The scope can focus on one process, function, site, system, vendor model or area of regulatory concern.
Yes. Selected deviations, CAPAs, changes, audits, training records, vendor files, metrics and management-review evidence can be sampled to evaluate operational effectiveness.
Yes. The assessment can prioritize inspection-relevant processes, critical records, repeat findings, overdue actions, governance and SME readiness.
Yes. Support can include remediation planning, QMS redesign, SOP development, CAPA review, implementation governance and effectiveness verification.
Yes. Document review, interviews, record sampling, workshops, reporting and remediation planning can be delivered remotely or through a hybrid model.